{"id":"docetaxel-d","safety":{"commonSideEffects":[{"rate":"75–80%","effect":"Neutropenia"},{"rate":"5–10%","effect":"Anemia"},{"rate":"5–10%","effect":"Thrombocytopenia"},{"rate":"20–35%","effect":"Peripheral neuropathy"},{"rate":"75–80%","effect":"Alopecia"},{"rate":"30–40%","effect":"Nausea/vomiting"},{"rate":"30–40%","effect":"Diarrhea"},{"rate":"15–20%","effect":"Mucositis"},{"rate":"2–5%","effect":"Hypersensitivity reactions"},{"rate":"5–10%","effect":"Fluid retention"}]},"_chembl":null,"_dailymed":{"setId":"8fb7d980-d6c7-468b-a9f0-adff16101a4b","title":"BEIZRAY ( DOCETAXEL ) KIT BEIZRAY ( DOCETAXEL ) KIT BEIZRAY (DOCETAXEL) INJECTION, SOLUTION [ZYDUS PHARMACEUTICALS USA INC.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Docetaxel is a taxane that binds to the β-tubulin subunit of microtubules and prevents their disassembly, leading to stabilization of the microtubule structure. This disrupts normal cell division by preventing the formation of the mitotic spindle, causing cells to arrest in the G2/M phase of the cell cycle and undergo apoptosis. It is effective against a broad range of solid tumors with high mitotic activity.","oneSentence":"Docetaxel stabilizes microtubules by binding to β-tubulin, preventing their depolymerization and causing cell cycle arrest and apoptosis in rapidly dividing cancer cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:09:48.692Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic breast cancer"},{"name":"Non-small cell lung cancer"},{"name":"Prostate cancer"},{"name":"Gastric adenocarcinoma"},{"name":"Head and neck cancer"}]},"trialDetails":[{"nctId":"NCT03178552","phase":"PHASE2, PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2017-09-22","conditions":"Non-Small Cell Lung Cancer","enrollment":1000},{"nctId":"NCT07246863","phase":"PHASE2","title":"Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC","status":"RECRUITING","sponsor":"CatalYm GmbH","startDate":"2025-10-07","conditions":"Metastatic Non-Squamous Non-Small Cell Lung Cancer, Adult Solid Tumor","enrollment":131},{"nctId":"NCT05381909","phase":"PHASE1","title":"A Study of BGB-24714 as Monotherapy and With Combination Therapies in Participants With Solid Tumors","status":"TERMINATED","sponsor":"BeiGene","startDate":"2022-07-06","conditions":"Solid Tumor, Adult","enrollment":157},{"nctId":"NCT02861573","phase":"PHASE1, PHASE2","title":"Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2016-11-17","conditions":"Metastatic Castration-Resistant Prostate Cancer","enrollment":1200},{"nctId":"NCT02624973","phase":"PHASE2","title":"PErsonalized TREatment of High-risk MAmmary Cancer - the PETREMAC Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Haukeland University Hospital","startDate":"2016-04-15","conditions":"Breast Cancer","enrollment":200},{"nctId":"NCT05415215","phase":"PHASE3","title":"A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants With Early or Locally Advanced/Inflammatory HER2-Positive Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2022-07-05","conditions":"Early Breast Cancer, Locally Advanced Breast Cancer, Inflammatory Breast Cancer","enrollment":346},{"nctId":"NCT07358689","phase":"PHASE2","title":"Toripalimab Combined With Platinum-based Chemotherapy With or Without H1 Receptor Antagonist in the Perioperative Treatment of Resectable Non-small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2026-01-30","conditions":"NSCLC","enrollment":120},{"nctId":"NCT05249426","phase":"PHASE1","title":"A Study to Test Whether Different Combinations of BI 765063, Ezabenlimab, Chemotherapy, Cetuximab, and BI 836880 Help People With Head and Neck Cancer or Liver Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Boehringer Ingelheim","startDate":"2022-04-12","conditions":"Head and Neck Squamous Cell Carcinoma (HNSCC)","enrollment":48},{"nctId":"NCT06908304","phase":"PHASE3","title":"A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC","status":"RECRUITING","sponsor":"Maia Biotechnology","startDate":"2025-12-08","conditions":"Carcinoma, Non-Small -Cell Lung","enrollment":300},{"nctId":"NCT02688803","phase":"PHASE4","title":"Multicentre Study to Determine the Feasibility of Using an Integrated Consent Model to Compare Three Standard of Care Regimens for The Treatment of Triple-Negative Breast Cancer in the Neoadjuvant/Adjuvant Setting (REaCT-TNBC)","status":"TERMINATED","sponsor":"Ottawa Hospital Research Institute","startDate":"2016-08-30","conditions":"Breast Cancer","enrollment":2},{"nctId":"NCT03137771","phase":"PHASE2","title":"Maintenance Chemotherapy With or Without Local Consolidative Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"NRG Oncology","startDate":"2017-04-07","conditions":"Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer","enrollment":218},{"nctId":"NCT02817633","phase":"PHASE1","title":"A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Tesaro, Inc.","startDate":"2016-07-08","conditions":"Neoplasms","enrollment":463},{"nctId":"NCT03678025","phase":"PHASE3","title":"Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer","status":"RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2018-09-24","conditions":"Castration Levels of Testosterone, Metastatic Prostatic Adenocarcinoma, Stage IV Prostate Cancer AJCC v8","enrollment":1273},{"nctId":"NCT06874114","phase":"","title":"An Observational Study to Learn More About Treatment Patterns and Factors Determining the Choice of Treatment in Canadian Men With Metastatic Hormone Sensitive Prostate Cancer in Routine Medical Care","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bayer","startDate":"2025-02-28","conditions":"Metastatic Hormone-sensitive Prostate Cancer","enrollment":700},{"nctId":"NCT06732856","phase":"PHASE1, PHASE2","title":"A Phase Ib/II Trial of Neoadjuvant Zolbetuximab Plus Docetaxel, Oxaliplatin and S-1 Chemotherapy in Patients With Locally Advanced Gastric Cancer","status":"RECRUITING","sponsor":"Asan Medical Center","startDate":"2025-04-04","conditions":"Stomach Neoplasm, Gastric (Stomach) Cancer","enrollment":57},{"nctId":"NCT05005728","phase":"PHASE2","title":"XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer","status":"COMPLETED","sponsor":"Xencor, Inc.","startDate":"2021-10-22","conditions":"Metastatic Castration-Resistant Prostate Cancer","enrollment":72},{"nctId":"NCT06439693","phase":"PHASE2","title":"The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2024-08-08","conditions":"Breast Cancer Female, Breast Cancer, Breast Cancer Metastatic","enrollment":72},{"nctId":"NCT03914443","phase":"PHASE1","title":"A Feasibility Trial of Nivolumab With Neoadjuvant CF or DCF Therapy for Locally Advanced Esophageal Carcinoma","status":"COMPLETED","sponsor":"National Cancer Center, Japan","startDate":"2019-05-07","conditions":"Locally Advanced Esophageal Squamous Cell Carcinoma","enrollment":37},{"nctId":"NCT04140526","phase":"PHASE1, PHASE2","title":"Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"OncoC4, Inc.","startDate":"2020-09-16","conditions":"Non Small Cell Lung Cancer, Advanced Solid Tumor, Metastatic Melanoma","enrollment":733},{"nctId":"NCT01652820","phase":"PHASE2","title":"Chemotherapy/Radiotherapy Versus Concomitant Chemotherapy Followed by Radiotherapy in Stage IIIB Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"Spanish Lung Cancer Group","startDate":"2001-10","conditions":"Non Small-cell Lung Cancer","enrollment":140},{"nctId":"NCT02664935","phase":"PHASE2","title":"National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Birmingham","startDate":"2015-05","conditions":"Non-Small Cell Lung Cancer, Carcinoma, Squamous Cell, Adenocarcinoma","enrollment":423},{"nctId":"NCT04947189","phase":"PHASE1, PHASE2","title":"Seviteronel in Combination With Chemotherapy in Androgen-receptor Positive Metastatic Triple-negative Breast Cancer","status":"RECRUITING","sponsor":"St Vincent's Hospital, Sydney","startDate":"2022-11-01","conditions":"Triple Negative Breast Cancer","enrollment":65},{"nctId":"NCT06942663","phase":"PHASE2","title":"Randomized Phase II Trial Evaluating DFS in The Absence of an Adjuvant Component of Perioperative Chemotherapy in Patients With Gastric Cancer","status":"NOT_YET_RECRUITING","sponsor":"Nizhny Novgorod Regional Clinical Oncology Center","startDate":"2025-04-15","conditions":"Gastric Cancer","enrollment":228},{"nctId":"NCT05919537","phase":"PHASE1","title":"Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hummingbird Bioscience","startDate":"2023-09-06","conditions":"Non-Small Cell Lung Cancer, Pancreatic Cancer, Locally Advanced Solid Tumor","enrollment":68},{"nctId":"NCT05543629","phase":"PHASE1, PHASE2","title":"A Study of BMS-986442 With Nivolumab With or Without Chemotherapy in Solid Tumors and Non-small Cell Lung Cancer","status":"TERMINATED","sponsor":"Bristol-Myers Squibb","startDate":"2022-10-04","conditions":"Advanced Solid Tumors, Non-small Cell Lung Cancer","enrollment":36},{"nctId":"NCT06868732","phase":"PHASE1","title":"Evaluation of JSKN016 Combination Therapy in Subjects with NSCLC","status":"NOT_YET_RECRUITING","sponsor":"Jiangsu Alphamab Biopharmaceuticals Co., Ltd","startDate":"2025-03-12","conditions":"Advanced Non-small Cell Lung Cancer","enrollment":288},{"nctId":"NCT03158129","phase":"PHASE2","title":"Nivolumab With or Without Ipilimumab or Chemotherapy in Treating Patients With Previously Untreated Stage I-IIIA Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2017-06-16","conditions":"Stage I Lung Non-Small Cell Cancer AJCC v7, Stage IA Lung Non-Small Cell Carcinoma AJCC v7, Stage IB Lung Non-Small Cell Carcinoma AJCC v7","enrollment":101},{"nctId":"NCT06737822","phase":"PHASE3","title":"Upfront Surgery Vs Induction Chemotherapy Followed By Surgery In Oral Cancers:","status":"RECRUITING","sponsor":"All India Institute of Medical Sciences, Jodhpur","startDate":"2024-12-20","conditions":"Oral Cancer, Head and Neck Neoplasms","enrollment":346},{"nctId":"NCT01924819","phase":"PHASE2, PHASE3","title":"Trial of Preoperative Therapy for Gastric and Esophagogastric Junction Adenocarcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Australasian Gastro-Intestinal Trials Group","startDate":"2009-09","conditions":"Gastric Cancer","enrollment":574},{"nctId":"NCT00324805","phase":"PHASE3","title":"Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2007-07-19","conditions":"Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage IIA Lung Non-Small Cell Carcinoma AJCC v7, Stage IIB Lung Non-Small Cell Carcinoma AJCC v7","enrollment":1501},{"nctId":"NCT05676203","phase":"PHASE3","title":"A Trial Comparing Docetaxel 75 mg/m2 (3w) Versus Docetaxel 50 mg/m2 (2w) in Combination With Darolutamide + ADT in mHSPC Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jena University Hospital","startDate":"2023-05-16","conditions":"Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)","enrollment":250},{"nctId":"NCT05431270","phase":"PHASE1, PHASE2","title":"Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 MAb, Administered Alone and in Combination with a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)","status":"RECRUITING","sponsor":"Phanes Therapeutics","startDate":"2022-08-11","conditions":"Non Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma","enrollment":40},{"nctId":"NCT04632992","phase":"PHASE2","title":"A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2021-01-13","conditions":"Advanced Unresectable or Metastatic Solid Malignancy","enrollment":252},{"nctId":"NCT04067713","phase":"","title":"Plasma Analysis for Response Assessment and to DIrect the manaGement of Metastatic Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University College, London","startDate":"2019-09-20","conditions":"Metastatic Prostate Cancer","enrollment":192},{"nctId":"NCT02009449","phase":"PHASE1","title":"A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2013-11-15","conditions":"Melanoma, Prostate Cancer, Ovarian Cancer","enrollment":353},{"nctId":"NCT01957436","phase":"PHASE3","title":"A Phase III Study for Patients With Metastatic Hormone-naïve Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNICANCER","startDate":"2013-11-13","conditions":"Metastatic Prostate Cancer","enrollment":1173},{"nctId":"NCT02229084","phase":"PHASE1, PHASE2","title":"Vaccination of High Risk Breast Cancer Patients","status":"COMPLETED","sponsor":"University of Arkansas","startDate":"2015-01-14","conditions":"Breast Cancer, Breast Neoplasms","enrollment":58},{"nctId":"NCT06656624","phase":"PHASE2","title":"Efficacy and Safety of Ribociclib Combined With AI Versus Physician&Amp;#39;s Choice of Chemotherapy Sequential Endocrine Therapy in ER Middle-low-expression/HER2-negative Advanced Breast Cancer (Rachel)","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2024-08-13","conditions":"Advanced Breast Cancer","enrollment":190},{"nctId":"NCT03971474","phase":"PHASE2","title":"Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial)","status":"COMPLETED","sponsor":"SWOG Cancer Research Network","startDate":"2019-05-28","conditions":"Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8","enrollment":166},{"nctId":"NCT06491082","phase":"","title":"Chemotherapy Induced Neuropathy in Cancer Patients","status":"RECRUITING","sponsor":"Swami Rama Himalayan University","startDate":"2022-11-23","conditions":"Chemotherapy-induced Peripheral Neuropathy","enrollment":124},{"nctId":"NCT03833440","phase":"PHASE2","title":"Precision Immuno-Oncology for Advanced Non-small Cell Lung Cancer Patients With PD-1 ICI Resistance","status":"ACTIVE_NOT_RECRUITING","sponsor":"Assistance Publique Hopitaux De Marseille","startDate":"2019-10-08","conditions":"Non-small Cell Lung Cancer","enrollment":114},{"nctId":"NCT06375707","phase":"PHASE2","title":"Efficacy and Safety of Ribociclib in Combination With NSAI Versus Physician's Choice of Chemotherapy Sequential Endocrine Therapy in HR+/HER2- Advanced Breast Cancer","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2024-01-09","conditions":"Advanced Breast Cancer","enrollment":144},{"nctId":"NCT04547153","phase":"PHASE2","title":"Infusional Fluorouracil and Weekly Docetaxel for Gastric Cancer With Bone Marrow Involvement and DIC","status":"COMPLETED","sponsor":"Sixth Affiliated Hospital, Sun Yat-sen University","startDate":"2021-01-15","conditions":"Gastric Cancer, Bone Marrow Metastasis, Disseminated Intravascular Coagulation","enrollment":24},{"nctId":"NCT02735239","phase":"PHASE1, PHASE2","title":"Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal Cancer","status":"COMPLETED","sponsor":"Ludwig Institute for Cancer Research","startDate":"2016-06-24","conditions":"Esophageal Cancer","enrollment":73},{"nctId":"NCT05148195","phase":"PHASE2","title":"A Phase II Study of Envofolimab and BD0801 With/Without Chemotherapy in Patients With Advanced Solid Tumors","status":"TERMINATED","sponsor":"Jiangsu Simcere Pharmaceutical Co., Ltd.","startDate":"2021-12-22","conditions":"Advanced Solid Tumor","enrollment":86},{"nctId":"NCT04062656","phase":"PHASE2","title":"Perioperative Immunotherapy vs. Chemo-immunotherapy in Patients With Advanced GC and AEG","status":"UNKNOWN","sponsor":"University Hospital, Essen","startDate":"2019-09-26","conditions":"Gastric Cancer, Adenocarcinoma of the Esophagogastric Junction","enrollment":21},{"nctId":"NCT00630032","phase":"PHASE3","title":"Safety and Efficacy Comparison of Docetaxel and Ixabepilone in Non Metastatic Poor Prognosis Breast Cancer","status":"COMPLETED","sponsor":"UNICANCER","startDate":"2007-09","conditions":"Breast Cancer","enrollment":762},{"nctId":"NCT00099086","phase":"PHASE1","title":"Docetaxel, Radiation Therapy, and Hormone Therapy in Treating Patients With Locally Advanced Prostate Cancer","status":"COMPLETED","sponsor":"Medical University of South Carolina","startDate":"2007-01-16","conditions":"Prostate Cancer","enrollment":20},{"nctId":"NCT06208033","phase":"EARLY_PHASE1","title":"SMET12 and Toripalimab Combined Chemotherapy in Patients With EGFR Positive Advanced Non-small Cell Lung Cancer (NSCLC)","status":"UNKNOWN","sponsor":"Fujian Cancer Hospital","startDate":"2024-01-10","conditions":"EGFR Positive Non-small Cell Lung Cancer","enrollment":40},{"nctId":"NCT06123494","phase":"PHASE3","title":"SHR-A1811 for Subjects With Her2-positive Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on or After First-line Anti-HER2 Therapy-containing Regimen","status":"RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2024-01-09","conditions":"HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma","enrollment":360},{"nctId":"NCT04221555","phase":"PHASE2","title":"Trial of Neoadjuvant Durvalumab Plus Docetaxel, Oxaliplatin, S-1 Followed by Surgery and Adjuvant Durvalumab Plus S-1 Chemotherapy in Potentially Resectable MMR Proficient Gastric or Gastroesophageal Junction Adenocarcinoma","status":"UNKNOWN","sponsor":"Asan Medical Center","startDate":"2020-05-13","conditions":"Resectable Gastric or Gastroesophageal Junction Adenocarcinoma","enrollment":68},{"nctId":"NCT04151563","phase":"PHASE1, PHASE2","title":"A Clinical Study Evaluating Nivolumab-containing Treatments in Patients With Advanced Non-small Cell Lung Cancer After Failing Previous PD-1/(L)1 Therapy and Chemotherapy","status":"WITHDRAWN","sponsor":"Bristol-Myers Squibb","startDate":"2021-04-15","conditions":"Carcinoma, Non-small Cell Lung Cancer","enrollment":""},{"nctId":"NCT03607656","phase":"PHASE2, PHASE3","title":"The Effect of Traditional Chinese Treatment Combined Adjuvant Chemotherapy in IIIb and IIIc Gastric Cancer","status":"COMPLETED","sponsor":"Shanghai University of Traditional Chinese Medicine","startDate":"2018-06-08","conditions":"Gastric Cancer Stage IIIB, Gastric Cancer Stage IIIC","enrollment":270},{"nctId":"NCT05125055","phase":"PHASE2, PHASE3","title":"Neoadjuvant Anti-PD-1 and TP Versus TPF on Pathological Response in OSCC","status":"RECRUITING","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2021-10-01","conditions":"Oral Squamous Cell Carcinoma, Neoadjvant Therapy, Anti-PD-1","enrollment":80},{"nctId":"NCT05673629","phase":"PHASE3","title":"Utidelone in Combination With AC Versus Docetaxel in Combination With AC for Neoadjuvant Chemotherapy in Patients With HER2-negative Breast Cancer","status":"UNKNOWN","sponsor":"Beijing Biostar Pharmaceuticals Co., Ltd.","startDate":"2023-05-30","conditions":"Breast Cancer","enrollment":552},{"nctId":"NCT05673590","phase":"PHASE3","title":"Utidelone Versus Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer","status":"UNKNOWN","sponsor":"Beijing Biostar Pharmaceuticals Co., Ltd.","startDate":"2023-05-12","conditions":"Locally Advanced or Metastatic Non-Small Cell Lung Cancer","enrollment":612},{"nctId":"NCT03840915","phase":"PHASE1, PHASE2","title":"M7824 in Combination With Chemotherapy in Stage IV Non-small Cell Lung Cancer (NSCLC)","status":"COMPLETED","sponsor":"EMD Serono Research & Development Institute, Inc.","startDate":"2019-04-02","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":70},{"nctId":"NCT01708993","phase":"PHASE2","title":"Reolysin in Previously Treated Advanced/Metastatic, Non Small Cell Lung Cancer Receiving Standard Salvage Therapy","status":"COMPLETED","sponsor":"Canadian Cancer Trials Group","startDate":"2012-12-10","conditions":"Non Small Cell Lung Cancer","enrollment":166},{"nctId":"NCT02057107","phase":"PHASE2","title":"SBRT With Cetuximab +/- Docetaxel Followed by Adjuvant Cetuximab +/- Docetaxel in Recurrent, Previously-Irradiated SCCHN","status":"COMPLETED","sponsor":"Heath Skinner","startDate":"2013-07-03","conditions":"Previously-Irradiated, Squamous Cell Carcinoma of the Head and Neck Cancer","enrollment":40},{"nctId":"NCT02154490","phase":"","title":"Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer","status":"COMPLETED","sponsor":"SWOG Cancer Research Network","startDate":"2014-07-08","conditions":"Recurrent Squamous Cell Lung Carcinoma, Stage IV Squamous Cell Lung Carcinoma AJCC v7","enrollment":1864},{"nctId":"NCT02740985","phase":"PHASE1","title":"A Phase 1 Clinical Study of AZD4635 in Patients With Advanced Solid Malignancies","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2016-06-17","conditions":"Advanced Solid Malignancies, Non-Small Cell Lung Cancer (NSCLC), Metastatic Castrate-Resistant Prostate Carcinoma (mCRPC)","enrollment":313},{"nctId":"NCT02607423","phase":"PHASE2","title":"Fludeoxyglucose F-18 PET/CT in Predicting Response to Chemotherapy in Patients With Stage IIIA Non-small Cell Lung Cancer That Can Be Removed by Surgery","status":"WITHDRAWN","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2015-11-19","conditions":"Stage IIIA Non-Small Cell Lung Cancer","enrollment":""},{"nctId":"NCT00268476","phase":"PHASE2, PHASE3","title":"Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Medical Research Council","startDate":"2005-07-08","conditions":"Prostate Cancer","enrollment":11992},{"nctId":"NCT05800054","phase":"NA","title":"Effect of NST Whole-course Nutritional Management on Nutritional Status and Adverse Reactions in Esophageal Cancer","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2021-01-01","conditions":"Esophageal Neoplasms, Adverse Drug Event","enrollment":210},{"nctId":"NCT00432172","phase":"PHASE2","title":"Selective Neoadjuvant Treatment According to Immunohistochemical Subtype for HER2 Negative Breast Cancer Patients","status":"COMPLETED","sponsor":"Spanish Breast Cancer Research Group","startDate":"2007-04-24","conditions":"Breast Cancer","enrollment":189},{"nctId":"NCT00841828","phase":"PHASE2","title":"Trastuzumab Versus Lapatinib as Neoadjuvant Treatment for Her2+ Patients","status":"COMPLETED","sponsor":"Spanish Breast Cancer Research Group","startDate":"2009-02","conditions":"Breast Cancer","enrollment":102},{"nctId":"NCT03386721","phase":"PHASE2","title":"Basket Study to Evaluate the Therapeutic Activity of Simlukafusp Alfa as a Combination Therapy in Participants With Advanced and/or Metastatic Solid Tumors","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2018-02-19","conditions":"Advanced/Metastatic Head and Neck, Oesophageal and Cervical Cancers","enrollment":256},{"nctId":"NCT02910219","phase":"PHASE2","title":"Diarrhea Prevention and Prophylaxis With Crofelemer in HER2 Positive Breast Cancer Patients","status":"COMPLETED","sponsor":"Sandra Swain","startDate":"2017-01-31","conditions":"Breast Cancer","enrollment":53},{"nctId":"NCT02504489","phase":"PHASE3","title":"Docetaxel + Plinabulin Compared to Docetaxel + Placebo in Patients With Advanced NSCLC","status":"COMPLETED","sponsor":"BeyondSpring Pharmaceuticals Inc.","startDate":"2015-12","conditions":"Non-Small Cell Lung Cancer","enrollment":559},{"nctId":"NCT03154749","phase":"PHASE2","title":"DCb (Docetaxel/Carboplatin) Versus EC-D (Epirubicin/Cyclophosphamide Followed by Docetaxe) as Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer","status":"COMPLETED","sponsor":"Guangdong Provincial People's Hospital","startDate":"2016-09-01","conditions":"Triple-Negative Breast Cancer","enrollment":93},{"nctId":"NCT02897050","phase":"PHASE2","title":"Trial of Neoadjuvant Docetaxel ± Metronomic Capecitabine/CTX Followed by FEC in Women With Operable Triple Negative Breast Cancer","status":"SUSPENDED","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2016-09","conditions":"Breast Cancer","enrollment":170},{"nctId":"NCT01547741","phase":"PHASE3","title":"Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer","status":"UNKNOWN","sponsor":"NSABP Foundation Inc","startDate":"2012-04","conditions":"Breast Cancer","enrollment":1871},{"nctId":"NCT02460367","phase":"PHASE1","title":"Immunotherapy Combination Study in Advanced Previously Treated Non-Small Cell Lung Cancer","status":"TERMINATED","sponsor":"NewLink Genetics Corporation","startDate":"2016-01","conditions":"Non-small Cell Lung Cancer, Progression of Non-small Cell Lung Cancer, Non-small Cell Lung Cancer Recurrent","enrollment":16},{"nctId":"NCT01362374","phase":"PHASE1","title":"Safety and Clinical Pharmacology of GDC-0068 in Combination With Docetaxel, Fluoropyrimidine Plus Oxaliplatin, Paclitaxel, or Enzalutamide in Participants With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2011-07-11","conditions":"Neoplasms","enrollment":122},{"nctId":"NCT04929548","phase":"PHASE4","title":"Exploratory Study of Neoadjuvant Treatment of HER2-positive Breast Cancer With Py in Combination With HP","status":"NOT_YET_RECRUITING","sponsor":"Wuhan University","startDate":"2022-01-05","conditions":"Breast Cancer","enrollment":20},{"nctId":"NCT05172518","phase":"PHASE3","title":"Utidelone Plus Capecitabine Versus Taxane Plus Capecitabine in HER2-negative Locally Advanced or Metastatic Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2022-03-01","conditions":"Breast Neoplasms, Locally Advanced or Metastatic Breast Cancer","enrollment":512},{"nctId":"NCT00193128","phase":"PHASE1, PHASE2","title":"Preoperative Therapy With Oxaliplatin/Docetaxel/Capecitabine and Radiation in Resectable Esophagus Cancer","status":"COMPLETED","sponsor":"SCRI Development Innovations, LLC","startDate":"2004-04","conditions":"Esophagus Cancer","enrollment":59},{"nctId":"NCT04009265","phase":"PHASE3","title":"Study Compare Adjuvant Chemotherapy, Chemoradiotherapy and Surgery Alone for pN1-2(pT1b-3N1-2M0) Esophageal Carcinoma","status":"RECRUITING","sponsor":"Fujian Medical University Union Hospital","startDate":"2019-08-23","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":819},{"nctId":"NCT04654403","phase":"NA","title":"Study of First-line Camrelizumab With or Without Chemotherapy for Advanced Esophageal Squamous Cell Cancer","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Zhengzhou University","startDate":"2022-01-01","conditions":"Esophageal Cancer","enrollment":337},{"nctId":"NCT02531737","phase":"PHASE2","title":"Nintedanib (Vargatef®) Plus Docetaxel in Second Line of Treatment in Patients With Lung Cancer","status":"COMPLETED","sponsor":"University Hospital, Limoges","startDate":"2015-09","conditions":"Lung Neoplasms","enrollment":59},{"nctId":"NCT04137640","phase":"PHASE4","title":"Palbociclib + Letrozole Versus Epirubicin + Cyclophosphamide and Sequential Docetaxel as Neoadjuvant Chemotherapy","status":"NOT_YET_RECRUITING","sponsor":"Shengjing Hospital","startDate":"2021-07-19","conditions":"Breast Cancer","enrollment":152},{"nctId":"NCT01254513","phase":"PHASE2","title":"Feasibility of a Chemotherapy With Docetaxel-Prednisone for Castration-resistant Metastatic Prostate Cancer Elderly Patients","status":"COMPLETED","sponsor":"UNICANCER","startDate":"2010-12-09","conditions":"Prostate Cancer","enrollment":66},{"nctId":"NCT01220128","phase":"PHASE2","title":"Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2011-04-11","conditions":"Neoplasms, Breast","enrollment":66},{"nctId":"NCT02574078","phase":"PHASE1, PHASE2","title":"A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2015-11-23","conditions":"Non-Small Cell Lung Cancer","enrollment":341},{"nctId":"NCT04563975","phase":"PHASE2","title":"Efficacy and Safety of Toripalimab Combined With Docetaxel or Nab-paclitaxel in Patients With Advanced Gastric Cancer","status":"UNKNOWN","sponsor":"Tao Zhang","startDate":"2020-07-02","conditions":"Gastric Cancer Stage IV","enrollment":54},{"nctId":"NCT04764149","phase":"","title":"Platinum Plus Low-dose Long-term Continuous Intravenous Infused 5-Fluorouracil in Recurrent Nasopharyngeal Carcinoma","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2019-11-01","conditions":"Nasopharyngeal Carcinoma","enrollment":801},{"nctId":"NCT02324088","phase":"PHASE3","title":"Interest of Maintenance Chemotherapy After Induction Treatment for Inflammatory Breast Cancer","status":"COMPLETED","sponsor":"UNICANCER","startDate":"2000-10","conditions":"Inflammatory Breast Cancer","enrollment":174},{"nctId":"NCT02036060","phase":"PHASE2","title":"Abiraterone Acetate in Combination With Docetaxel After Disease Progression to Abiraterone Acetate in Metastatic Castration Resistant Prostate Cancer.","status":"COMPLETED","sponsor":"Spanish Oncology Genito-Urinary Group","startDate":"2014-02-07","conditions":"Metastatic Prostate Cancer","enrollment":119},{"nctId":"NCT04499118","phase":"PHASE2","title":"AT Versus TP as Neoadjuvant Chemotherapy in Patients With HER2-negative Early Breast Cancer","status":"UNKNOWN","sponsor":"Sichuan Provincial People's Hospital","startDate":"2020-08","conditions":"HER2-negative Breast Cancer","enrollment":100},{"nctId":"NCT04472403","phase":"","title":"Platinum Plus Low-dose Long-term Continuous Intravenous Infused 5-Fluorouracil in Metastatic Nasopharyngeal Carcinoma","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2019-11-26","conditions":"Nasopharyngeal Carcinoma, Metastasis, Chemotherapy","enrollment":2000},{"nctId":"NCT01792050","phase":"PHASE2","title":"Study of Chemotherapy in Combination With IDO Inhibitor in Metastatic Breast Cancer","status":"COMPLETED","sponsor":"NewLink Genetics Corporation","startDate":"2013-02","conditions":"Metastatic Breast Cancer","enrollment":169},{"nctId":"NCT00582582","phase":"PHASE2","title":"Study of Docetaxel With Doxercalciferol or Placebo for Advanced Prostate Cancer","status":"TERMINATED","sponsor":"University of Wisconsin, Madison","startDate":"2002-04","conditions":"Prostate Cancer","enrollment":70},{"nctId":"NCT00515411","phase":"PHASE2","title":"Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2006-10-23","conditions":"Gastroesophageal Junction Adenocarcinoma, Gastric Cancer","enrollment":111},{"nctId":"NCT02456571","phase":"","title":"CTC Immune Checkpoint","status":"COMPLETED","sponsor":"Duke University","startDate":"2016-11","conditions":"Prostate Cancer","enrollment":38},{"nctId":"NCT02795572","phase":"PHASE2","title":"Nutraceuticals Versus Usual Care in the Prevention or Reduction of CIPN in Patients Treated With Docetaxel as Neoadjuvant/Adjuvant Breast Cancer Therapy","status":"TERMINATED","sponsor":"AHS Cancer Control Alberta","startDate":"2017-06-27","conditions":"Peripheral Neuropathy in Breast Cancer Patient","enrollment":13},{"nctId":"NCT01181401","phase":"PHASE2","title":"InductionChemo-Radio-Antibody-Treatment","status":"COMPLETED","sponsor":"Charite University, Berlin, Germany","startDate":"2010-08","conditions":"Squamous Cell Carcinoma of the Head, Squamous Cell Carcinoma of the Neck","enrollment":94},{"nctId":"NCT00828386","phase":"PHASE3","title":"Induction Chemotherapy and Chemoradiotherapy in Nasopharyngeal Cancers","status":"TERMINATED","sponsor":"Groupe Oncologie Radiotherapie Tete et Cou","startDate":"2009-01","conditions":"Nasopharyngeal Cancers","enrollment":83},{"nctId":"NCT03671265","phase":"NA","title":"Combination of Chemotherapy Plus RT and SHR-1210 to Treat Patients With ESCC","status":"UNKNOWN","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2018-09-17","conditions":"Esophageal Cancer","enrollment":20},{"nctId":"NCT03723343","phase":"","title":"GP-induced Chemotherapy Combined With IMRT and TPF-induced Chemotherapy Combined With IMRT in the Treatment of Distant Metastatic Nasopharyngeal Carcinoma","status":"UNKNOWN","sponsor":"Guiyang Medical University","startDate":"2018-10-18","conditions":"Advanced Nasopharyngeal Carcinoma","enrollment":146},{"nctId":"NCT01935947","phase":"PHASE2","title":"Azacitidine and Entinostat Before Chemotherapy in Treating Patients With Advanced Non-small Cell Lung Cancer","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2013-05","conditions":"Recurrent Non-Small Cell Lung Carcinoma, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer","enrollment":17}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Taxotere"],"phase":"marketed","status":"active","brandName":"Docetaxel (D)","genericName":"Docetaxel (D)","companyName":"BeyondSpring Pharmaceuticals Inc.","companyId":"beyondspring-pharmaceuticals-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Docetaxel stabilizes microtubules by binding to β-tubulin, preventing their depolymerization and causing cell cycle arrest and apoptosis in rapidly dividing cancer cells. Used for Metastatic breast cancer, Non-small cell lung cancer, Prostate cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}